Dexamethasone Implant, Given at 6-Month Intervals, Sustained Improvement for 3 Years

 

The dexamethasone intravitreal implant (Ozurdex, Allergan) produced sustained retinal structural improvement in patients with diabetic macular edema (DME) when administered in doses of 0.7 mg or 0.35 mg at 6-month intervals, according to a study published in the British Journal of Ophthalmology.1

Researchers analyzed data from two multicenter, masked, phase 3 studies with identical protocols. Patients in those studies were randomly assigned to receive treatment with the dexamethasone intravitreal implant 0.7 mg or 0.35 mg or sham. Entry criteria included DME diagnosis, BCVA of 34 to 68 ETDRS letters, and central subfield retinal thickness of at least 300 µm. Patients were followed for 3 years and treated at intervals of at least 6 months.

After 3 years, eyes in the treatment group showed mean improvement in macular edema grade compared with eyes in the sham group (P < .05). Eyes in the 0.7-mg group showed mean delayed time to onset of two-step progression in diabetic retinopathy severity by approximately 12 months.

1. Danis RP, Sadda S, Li XY, et al. Anatomical effects of dexamethasone intravitreal implant in diabetic macular oedema: a pooled analysis of 3-year phase III trials [published online ahead of print November 18, 2015]. Br J Ophthalmol.

 

Contact Info

Bryn Mawr Communications LLC
1008 Upper Gulph Road, Suite 200
Wayne, PA 19087

Phone: 484-581-1800
Fax: 484-581-1818

Karen Roman
Editor-in-Chief
484-581-1827
kroman@bmctoday.com

Janet Burk
Publisher
214-394-3551
jburk@bmctoday.com

About Retina Today

Retina Today is a publication that delivers the latest research and clinical developments from areas such as medical retina, retinal surgery, vitreous, diabetes, retinal imaging, posterior segment oncology and ocular trauma. Each issue provides insight from well-respected specialists on cutting-edge therapies and surgical techniques that are currently in use and on the horizon.